Matrix metalloproteinases destroy the ECM and MMP-9 levels were decreased in SSc-PAH and increased with bosentin therapy, while MMP-12 was increased in patients with DU and NVC changes [116,117,118,119]. Here, MMP9 is linked to systemic sclerosis.